Insider Transactions in Q4 2022 at Prime Medicine, Inc. (PRME)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 24
2022
|
Thomas Cahill Director |
BUY
Open market or private purchase
|
Indirect |
400,000
+7.01%
|
$6,800,000
$17.0 P/Share
|
|
Oct 24
2022
|
Thomas Cahill Director |
BUY
Conversion of derivative security
|
Indirect |
4,905,679
+50.0%
|
-
|
|
Oct 24
2022
|
David R. Liu > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
321,665
+1.5%
|
-
|
|
Oct 24
2022
|
Robert Nelsen Director |
BUY
Conversion of derivative security
|
Indirect |
11,472,674
+50.0%
|
-
|
|
Oct 24
2022
|
Robert Nelsen Director |
BUY
Open market or private purchase
|
Indirect |
800,000
+6.13%
|
$13,600,000
$17.0 P/Share
|
|
Oct 24
2022
|
Arch Venture Partners X, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
800,000
+6.13%
|
$13,600,000
$17.0 P/Share
|
|
Oct 24
2022
|
Arch Venture Partners X, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
11,456,594
+50.0%
|
-
|
|
Oct 24
2022
|
Gv 2019 Gp, L.L.C. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
800,000
+6.49%
|
$13,600,000
$17.0 P/Share
|
|
Oct 24
2022
|
Gv 2019 Gp, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
12,484,688
+50.0%
|
-
|
|
Oct 24
2022
|
Fmr LLC |
BUY
Conversion of derivative security
|
Indirect |
8,462,946
+33.64%
|
-
|